MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Iovance Biotherapeutics Inc

Затворен

СекторЗдравеопазване

2.24 15.46

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.94

Максимум

2.24

Ключови измерители

By Trading Economics

Приходи

-38M

-116M

Продажби

-24M

49M

Марж на печалбата

-235.51

Служители

838

EBITDA

-35M

-110M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+379.38% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-498M

671M

Предишно отваряне

-13.22

Предишно затваряне

2.24

Настроения в новините

By Acuity

50%

50%

154 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Iovance Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.07.2025 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- 2nd Update

16.07.2025 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Santos 2Q Output Rises 1% as Takeover Campaign Continues

16.07.2025 г., 23:00 ч. UTC

Придобивния, сливания и поглъщания

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- Update

16.07.2025 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Alimentation Couche-Tard Withdraws Seven & i Acquisition Proposal

16.07.2025 г., 23:44 ч. UTC

Пазарно говорене

Gold Steady; Geopolitical Tensions in Middle East Support -- Market Talk

16.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Fall as Yen Strengthens -- Market Talk

16.07.2025 г., 23:24 ч. UTC

Пазарно говорене

Australian Job Market Data to Shape RBA Calls -- Market Talk

16.07.2025 г., 23:18 ч. UTC

Придобивния, сливания и поглъщания

Santos Now Expects 2025 Production of 90 Million-95 Million BOE

16.07.2025 г., 23:18 ч. UTC

Придобивния, сливания и поглъщания

Santos Cuts Top End of 2025 Production Guidance

16.07.2025 г., 23:17 ч. UTC

Придобивния, сливания и поглъщания

Santos: Production Recovery Underway in Cooper Basin

16.07.2025 г., 23:17 ч. UTC

Придобивния, сливания и поглъщания

Santos: Over 200 Wells, Several Upstream Compressors in Cooper Basin Shut In

16.07.2025 г., 23:17 ч. UTC

Придобивния, сливания и поглъщания

Santos: Cooper Basin Production Impacted by Floods in 2Q

16.07.2025 г., 23:16 ч. UTC

Придобивния, сливания и поглъщания

Santos: Pikka Phase 1 Project in Alasia 89% Complete

16.07.2025 г., 23:16 ч. UTC

Придобивния, сливания и поглъщания

Santos Keeps 2025 Major Development Project Capex Guidance Unchanged

16.07.2025 г., 23:13 ч. UTC

Придобивния, сливания и поглъщания

Santos Had Gearing of 20.5% at End-June, Excluding Operating Leases

16.07.2025 г., 23:13 ч. UTC

Придобивния, сливания и поглъщания

Santos Says Moomba CCS Phase 1 Project Performing to Expectations

16.07.2025 г., 23:12 ч. UTC

Придобивния, сливания и поглъщания

Santos Narrows 2025 Unit Production Cost Guidance to US$7.00-US$7.40/BOE

16.07.2025 г., 23:12 ч. UTC

Придобивния, сливания и поглъщания

Santos 1H Free Cash Flow From Operations US$1.1 Billion

16.07.2025 г., 23:11 ч. UTC

Придобивния, сливания и поглъщания

Santos 2Q Free Cash Flow From Operations US$620 Million

16.07.2025 г., 23:11 ч. UTC

Придобивния, сливания и поглъщания

Santos 2Q Oil, Natural Gas Output 22.2 Million BOE

16.07.2025 г., 23:11 ч. UTC

Придобивния, сливания и поглъщания

Santos 2Q Oil, Natural Gas Sales Volumes 23.9 Million BOE

16.07.2025 г., 23:11 ч. UTC

Придобивния, сливания и поглъщания

Santos 2Q Oil, Natural Gas Sales Volumes Up 3% on 1Q

16.07.2025 г., 23:11 ч. UTC

Придобивния, сливания и поглъщания

Santos 2Q Oil, Natural Gas Output Up 1% on 1Q

16.07.2025 г., 22:43 ч. UTC

Пазарно говорене

Alcoa Using High Costs of More Production to Battle Tariff -- Market Talk

16.07.2025 г., 22:35 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

16.07.2025 г., 22:35 ч. UTC

Пазарно говорене
Печалби

Replacing Aluminum Imports With U.S. Production Not Seen Feasible -- Market Talk

16.07.2025 г., 22:33 ч. UTC

Пазарно говорене
Печалби

Alcoa Will Continue to Ship Aluminum Outside of the U.S. -- Market Talk

16.07.2025 г., 22:28 ч. UTC

Пазарно говорене
Печалби

Aluminum Price in U.S. Doesn't Offset Tariff Costs, Alcoa says -- Market Talk

16.07.2025 г., 22:22 ч. UTC

Пазарно говорене
Печалби

Market Talk Roundup: Latest on U.S. Politics

16.07.2025 г., 22:22 ч. UTC

Пазарно говорене
Печалби

Alcoa Considers Restart of Idle Capacity at Indiana Smelter -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Iovance Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

379.38% нагоре

12-месечна прогноза

Среден 9.3 USD  379.38%

Висок 25 USD

Нисък 1 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Iovance Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

6

Купи

4

Задържане

1

Продай

Техническа оценка

By Trading Central

3.0208 / 3.5Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

154 / 376 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.